Artiva appoints Alison Moore Ph.D. as Class III director and committee member

Artiva Biotherapeutics, Inc.

Alison Moore appointed as Class III director with term expiring at 2027 annual meeting; also joins Technical Operations Committee.
Dr. Moore is Chief Technical Officer at Codexis (since Oct 2024); previously CTO/EVP at Allogene Therapeutics and SVP at Amgen.
Receives annual cash retainer of $40,000 for board service and $15,000 for Technical Operations Committee service.
Granted option to purchase 27,500 shares, one-third vested immediately, remainder vesting monthly over two years.
Will receive automatic annual option grants of 13,750 shares at each annual meeting, vesting over one year.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alison Moore

Class III Director

ARTV · Artiva Biotherapeutics, Inc.

Effective: 2024-10-21
Filed: October 22, 2024, 7:59 PM ET

appointed Alison Moore, Ph.D. as (i) a Class III director of the Company, with a term of office expiring at the 2027 annual meeting of stockholders and (ii) a member of the Technical Operations Committee of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alison Moore was appointed as Class III Director at Artiva Biotherapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

appointed Alison Moore, Ph.D. as (i) a Class III director of the Company, with a term of office expiring at the 2027 annual meeting of stockholders and (ii) a member of the Technical Operations Committee of the Board

View on SEC.gov

Artiva Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-241059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.